<DOC>
	<DOCNO>NCT00696891</DOCNO>
	<brief_summary>This study conduct compare immunogenicity , reactogenicity safety Engerix™-B HBV-MPL vaccine hepatitis B infection elderly population</brief_summary>
	<brief_title>Study Comparing Immunogenicity , Reactogenicity Safety GSK Bios ' HBV-MPL Vaccine With That Engerix™-B Adults</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age : 50 70 year old . Good physical condition establish clinical examination history take time entry . Female participant risk become pregnant contraceptive programme necessary study period . Written inform consent obtain subject Positive screen antiHBV antibody . Elevated serum liver enzymes History significant persisting hematologic , hepatic , renal , cardiac respiratory disease . Any acute disease moment entry . Chronic alcohol consumption . Hepatomegaly , right upper quadrant abdominal pain tenderness . Any chronic drug treatment , include treatment immunosuppressive drug , investigator 's opinion , preclude inclusion study . History allergic disease likely stimulate component vaccine . Simultaneous participation clinical trial . Previous vaccination recombinant hepatitis B vaccine . Previous vaccination MPL contain vaccine . Administration immunoglobulins past 6 month whole study period Vaccination one week one week dose study vaccine</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Adjuvanted hepatitis B vaccine , hepatitis B , Engerix™-B</keyword>
</DOC>